Oragenics (NYSE:OGEN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Sunday morning. The firm issued a sell rating on the stock.

Oragenics Trading Up 1.0 %

Shares of NYSE:OGEN opened at $1.05 on Friday. The company has a market cap of $4.70 million, a P/E ratio of -0.12 and a beta of 0.50. The firm’s 50-day simple moving average is $1.57. Oragenics has a fifty-two week low of $0.97 and a fifty-two week high of $7.74.

Oragenics (NYSE:OGEN) last released its quarterly earnings results on Wednesday, May 15th. The company reported ($0.70) earnings per share for the quarter.

Institutional Trading of Oragenics

An institutional investor recently bought a new position in Oragenics stock. Virtu Financial LLC purchased a new stake in Oragenics, Inc. (NYSE:OGEN) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned approximately 0.51% of Oragenics as of its most recent filing with the Securities and Exchange Commission (SEC). 18.71% of the stock is currently owned by institutional investors and hedge funds.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.